Amgen reported strong Q2 financial results, with revenue and adjusted EPS growing 14% and 19% respectively. The company raised its adjusted EPS guidance, highlighting strong demand for key products like Aranesp and Neulasta, improved gross margins, and robust pipeline progress. This optimistic outlook and solid performance are likely to positively impact the stock price in the short term.

[1]